The approval and commercialization of Oxervate (cenegermin-bkbj, Dompé) in the United States has improved our ability to treat corneal persistent epithelial defects (PEDs) or corneal ...
The rationale for the study was anecdotal reports of the effects of breast milk used by mothers to treat blocked tear ducts, ...
ARLINGTON, Mass. - KALA BIO, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on developing treatments for rare and severe eye diseases, announced a change in its executive leadership on Monday ...
On the left eye, the patient had conjunctival congestion and hyperemia, a central 2- × 2-mm corneal epithelial defect with deep stromal infiltration, endothelial plaque, moderate anterior chamber ...
OSN, a roundtable discusses the management of epithelial ingrowth after LASIK, neurotrophic keratitis and Demodex blepharitis ...
One eye with membranous keratoconjunctivitis with symblepharon showed resolution of corneal epithelial defect on the seventh day. The ocular surface healed completely with no symblepharon at the ...
Bazemore expressed his commitment to advancing KALA's lead product candidate, KPI-012, which is currently in Phase 2b trials for treating persistent corneal epithelial defect (PCED). Bazemore has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback